Reported Earnings • May 22
Full year 2026 earnings released: EPS: ₹4.82 (vs ₹4.10 in FY 2025) Full year 2026 results: EPS: ₹4.82 (up from ₹4.10 in FY 2025). Revenue: ₹1.64b (up 41% from FY 2025). Net income: ₹60.6m (up 17% from FY 2025). Profit margin: 3.7% (down from 4.4% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹128, the stock trades at a trailing P/E ratio of 33.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 171% over the past three years. New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (3.3% net profit margin). Market cap is less than US$100m (₹1.48b market cap, or US$15.7m). Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹110, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 147% over the past three years. Buy Or Sell Opportunity • Apr 06
Now 22% overvalued Over the last 90 days, the stock has fallen 17% to ₹86.40. The fair value is estimated to be ₹70.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 23%. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹0.42 (vs ₹0.17 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.42 (up from ₹0.17 in 3Q 2025). Revenue: ₹374.0m (up 30% from 3Q 2025). Net income: ₹5.28m (up 142% from 3Q 2025). Profit margin: 1.4% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 27% per year. Buy Or Sell Opportunity • Jan 21
Now 20% overvalued Over the last 90 days, the stock has fallen 16% to ₹101. The fair value is estimated to be ₹84.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 29%. Buy Or Sell Opportunity • Dec 31
Now 22% overvalued Over the last 90 days, the stock has fallen 19% to ₹103. The fair value is estimated to be ₹84.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 29%. New Risk • Dec 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (3.3% net profit margin). Market cap is less than US$100m (₹1.26b market cap, or US$14.0m). Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹99.80, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 86% over the past three years. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹127, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past three years. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Profit margins are more than 30% lower than last year (3.3% net profit margin). Market cap is less than US$100m (₹1.59b market cap, or US$17.9m). Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: ₹1.71 (vs ₹1.61 in 2Q 2025) Second quarter 2026 results: EPS: ₹1.71 (up from ₹1.61 in 2Q 2025). Revenue: ₹415.5m (up 37% from 2Q 2025). Net income: ₹21.6m (up 6.2% from 2Q 2025). Profit margin: 5.2% (down from 6.7% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 23% per year. Announcement • Sep 05
Lactose (India) Limited, Annual General Meeting, Sep 30, 2025 Lactose (India) Limited, Annual General Meeting, Sep 30, 2025, at 12:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹116, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past three years. Announcement • Aug 22
Lactose (India) Limited Appoints Kishor Patel as Additional Non Executive Independent Director, Effective 22 August 2025 The board of directors of Lactose (India) Limited at its meeting held on 22 August 2025, considered and approved the Appointment of Mr. Kishor Patel as an Additional Non Executive Independent Director. Date of appointment: 22nd August 2025. Mr. Kishor Patel is a Mechanical Engineer and holds Marketing and Material Management degree. Further, he is also ISO certified Auditor. He has tot al experience of 38 years of working in different capacities in various industries. He was previously associated with Colgate Contract Fillers for 6 years as a Sit e Head and with PGI for 24 years. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹1.19 (vs ₹1.80 in 1Q 2025) First quarter 2026 results: EPS: ₹1.19 (down from ₹1.80 in 1Q 2025). Revenue: ₹399.9m (up 36% from 1Q 2025). Net income: ₹15.0m (down 34% from 1Q 2025). Profit margin: 3.7% (down from 7.7% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Aug 09
Lactose (India) Limited to Report Q1, 2026 Results on Aug 13, 2025 Lactose (India) Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Reported Earnings • Jun 02
Full year 2025 earnings released: EPS: ₹4.10 (vs ₹5.39 in FY 2024) Full year 2025 results: EPS: ₹4.10 (down from ₹5.39 in FY 2024). Revenue: ₹1.18b (up 3.5% from FY 2024). Net income: ₹51.6m (down 24% from FY 2024). Profit margin: 4.4% (down from 6.0% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹107, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 84% over the past three years. Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹0.17 (vs ₹2.09 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.17 (down from ₹2.09 in 3Q 2024). Revenue: ₹287.2m (down 12% from 3Q 2024). Net income: ₹2.19m (down 92% from 3Q 2024). Profit margin: 0.8% (down from 8.1% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹153, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 180% over the past three years. Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹195, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 415% over the past three years. Reported Earnings • Oct 16
Second quarter 2025 earnings released: EPS: ₹1.61 (vs ₹0.64 in 2Q 2024) Second quarter 2025 results: EPS: ₹1.61 (up from ₹0.64 in 2Q 2024). Revenue: ₹304.5m (up 25% from 2Q 2024). Net income: ₹20.3m (up 152% from 2Q 2024). Profit margin: 6.7% (up from 3.3% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 65% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹170, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 43x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years. Announcement • Oct 10
Lactose (India) Limited to Report Q2, 2025 Results on Oct 15, 2024 Lactose (India) Limited announced that they will report Q2, 2025 results on Oct 15, 2024 Announcement • Sep 13
Lactose (India) Limited, Annual General Meeting, Sep 30, 2024 Lactose (India) Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2025 earnings released First quarter 2025 results: Revenue: ₹296.8m (up 8.1% from 1Q 2024). Net income: ₹22.7m (up 137% from 1Q 2024). Profit margin: 7.6% (up from 3.5% in 1Q 2024). The increase in margin was driven by higher revenue. Announcement • Aug 07
Lactose (India) Limited to Report Q1, 2025 Results on Aug 12, 2024 Lactose (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹173, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 451% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹5.39 (vs ₹0.96 in FY 2023) Full year 2024 results: EPS: ₹5.39 (up from ₹0.96 in FY 2023). Revenue: ₹1.15b (up 75% from FY 2023). Net income: ₹67.9m (up 462% from FY 2023). Profit margin: 5.9% (up from 1.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 66% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹136, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 291% over the past three years. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹2.09 (vs ₹0.11 in 3Q 2023) Third quarter 2024 results: EPS: ₹2.09 (up from ₹0.11 in 3Q 2023). Revenue: ₹328.8m (up 93% from 3Q 2023). Net income: ₹26.3m (up ₹24.8m from 3Q 2023). Profit margin: 8.0% (up from 0.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹144, the stock trades at a trailing P/E ratio of 64.9x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 501% over the past three years. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹114, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 365% over the past three years. New Risk • Nov 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (2.9% net profit margin). Market cap is less than US$100m (₹1.22b market cap, or US$14.6m). Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹96.55, the stock trades at a trailing P/E ratio of 43.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 261% over the past three years. Valuation Update With 7 Day Price Move • Nov 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹76.88, the stock trades at a trailing P/E ratio of 34.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 223% over the past three years. Reported Earnings • Nov 04
Second quarter 2024 earnings released: EPS: ₹0.64 (vs ₹0.07 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.64 (up from ₹0.07 in 2Q 2023). Revenue: ₹246.8m (up 87% from 2Q 2023). Net income: ₹8.06m (up ₹7.19m from 2Q 2023). Profit margin: 3.3% (up from 0.7% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 16
First quarter 2024 earnings released: EPS: ₹0.76 (vs ₹0.07 in 1Q 2023) First quarter 2024 results: EPS: ₹0.76 (up from ₹0.07 in 1Q 2023). Revenue: ₹277.5m (up 188% from 1Q 2023). Net income: ₹9.57m (up ₹8.70m from 1Q 2023). Profit margin: 3.4% (up from 0.9% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹59.29, the stock trades at a trailing P/E ratio of 61.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 218% over the past three years. Reported Earnings • Jun 03
Full year 2023 earnings released: EPS: ₹0.96 (vs ₹2.10 in FY 2022) Full year 2023 results: EPS: ₹0.96 (down from ₹2.10 in FY 2022). Revenue: ₹665.3m (up 45% from FY 2022). Net income: ₹12.1m (down 51% from FY 2022). Profit margin: 1.8% (down from 5.3% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹0.11 (vs ₹0.19 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.11 (down from ₹0.19 in 3Q 2022). Revenue: ₹170.2m (up 40% from 3Q 2022). Net income: ₹1.45m (down 33% from 3Q 2022). Profit margin: 0.8% (down from 1.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Announcement • Feb 07
Lactose (India) Limited to Report Q3, 2023 Results on Feb 14, 2023 Lactose (India) Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Nov 17
Second quarter 2023 earnings released: EPS: ₹0.07 (vs ₹0.28 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.07 (down from ₹0.28 in 2Q 2022). Revenue: ₹133.7m (up 23% from 2Q 2022). Net income: ₹869.0k (down 73% from 2Q 2022). Profit margin: 0.7% (down from 3.0% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth. Announcement • Nov 05
Lactose (India) Limited to Report Q2, 2023 Results on Nov 14, 2022 Lactose (India) Limited announced that they will report Q2, 2023 results at 3:30 PM, Indian Standard Time on Nov 14, 2022 Buying Opportunity • Sep 27
Now 20% undervalued Over the last 90 days, the stock is up 9.7%. The fair value is estimated to be ₹84.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: ₹0.07 (vs ₹0.57 loss in 1Q 2022) First quarter 2023 results: EPS: ₹0.07 (up from ₹0.57 loss in 1Q 2022). Revenue: ₹96.2m (up 12% from 1Q 2022). Net income: ₹872.0k (up ₹7.41m from 1Q 2022). Profit margin: 0.9% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 44% per year. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improved over the past week After last week's 17% share price gain to ₹86.00, the stock trades at a trailing P/E ratio of 44.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 299% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 17% share price gain to ₹74.05, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 244% over the past three years. Buying Opportunity • Jun 29
Now 23% undervalued Over the last 90 days, the stock is up 2.4%. The fair value is estimated to be ₹79.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹72.95, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years. Reported Earnings • May 30
Full year 2022 earnings released: EPS: ₹2.10 (vs ₹2.40 loss in FY 2021) Full year 2022 results: EPS: ₹2.10 (up from ₹2.40 loss in FY 2021). Revenue: ₹459.4m (up 31% from FY 2021). Net income: ₹24.5m (up ₹49.3m from FY 2021). Profit margin: 5.3% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings. Announcement • May 26
Lactose (India) Limited, Annual General Meeting, Jun 17, 2022 Lactose (India) Limited, Annual General Meeting, Jun 17, 2022, at 12:00 Indian Standard Time. Location: SURVEY NO.6, VILLAGE POICHA (RANIA), SAVLI Baroda Gujarat India Agenda: To consider and adopt the Audited Financial Statements of the Company for the financial year ended 31 March 2022; to appoint Statutory Auditors and to fix their remuneration and in this regard; to consider appointment of Directors; and to consider any other matters. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improved over the past week After last week's 23% share price gain to ₹90.90, the stock trades at a trailing P/E ratio of 46.7x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 175% over the past three years. Reported Earnings • Feb 16
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.19 (up from ₹0.49 loss in 3Q 2021). Revenue: ₹122.6m (up 19% from 3Q 2021). Net income: ₹2.14m (up ₹7.09m from 3Q 2021). Profit margin: 1.7% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Mahendrakumar Singhi Omprakash was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 18
Second quarter 2022 earnings released: EPS ₹0.28 (vs ₹0.87 loss in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹109.5m (up 32% from 2Q 2021). Net income: ₹3.20m (up ₹12.0m from 2Q 2021). Profit margin: 2.9% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 18
First quarter 2022 earnings released: ₹0.57 loss per share (vs ₹1.34 loss in 1Q 2021) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: ₹86.6m (up 37% from 1Q 2021). Net loss: ₹6.54m (loss narrowed 52% from 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 24
Full year 2021 earnings released: ₹2.40 loss per share (vs ₹0.071 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: ₹349.6m (down 13% from FY 2020). Net loss: ₹24.8m (down ₹25.5m from profit in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Mar 01
New 90-day high: ₹29.00 The company is up 12% from its price of ₹25.95 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Feb 14
Third quarter 2021 earnings released: ₹0.49 loss per share (vs ₹0.03 profit in 3Q 2020) The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: ₹102.8m (up 3.3% from 3Q 2020). Net loss: ₹4.95m (down ₹5.26m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 74% per year but the company’s share price has only fallen by 44% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 25
New 90-day high: ₹25.65 The company is up 1.0% from its price of ₹25.35 on 24 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Nov 13
Second quarter 2021 earnings released: ₹0.87 loss per share The company reported a poor second quarter result with weaker earnings, revenues and control over expenses. Second quarter 2021 results: Revenue: ₹83.8m (down 19% from 2Q 2020). Net loss: ₹8.83m (down ₹9.15m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 63% per year but the company’s share price has only fallen by 46% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 14
New 90-day low: ₹17.05 The company is down 10.0% from its price of ₹18.85 on 16 July 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 17% over the same period. Announcement • Jun 28
Lactose (India) Limited to Report Q4, 2020 Results on Jun 30, 2020 Lactose (India) Limited announced that they will report Q4, 2020 results on Jun 30, 2020 
